Equities

Unicocell Biomed Co Ltd

6794:TAI

Unicocell Biomed Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)78.40
  • Today's Change0.00 / 0.00%
  • Shares traded7.00k
  • 1 Year change+2.08%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Unicocell Biomed Co Ltd grew revenues 70.79% from 14.40m to 24.59m while net income improved from a loss of 91.16m to a smaller loss of 84.11m.
Gross margin66.09%
Net profit margin-570.24%
Operating margin-629.34%
Return on assets-14.06%
Return on equity-15.95%
Return on investment-14.42%
More ▼

Cash flow in TWDView more

In 2023, cash reserves at Unicocell Biomed Co Ltd fell by 33.74m. Cash Flow from Financing totalled 339.01m or 1,378.69% of revenues. In addition the company used 65.55m for operations while cash used for investing totalled 307.20m.
Cash flow per share-1.39
Price/Cash flow per share--
Book value per share12.32
Tangible book value per share12.32
More ▼

Balance sheet in TWDView more

Unicocell Biomed Co Ltd has a Debt to Total Capital ratio of 9.02%, a lower figure than the previous year's 11.11%.
Current ratio29.82
Quick ratio29.58
Total debt/total equity0.0991
Total debt/total capital0.0902
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.